Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Persistent Symptoms Following SARS-CoV-2 Infection by Antibody Status in Nonhospitalized Children and Adolescents.
Messiah SE, Hao T, DeSantis SM, Swartz MD, Talebi Y, Kohl HW 3rd, Zhang S, Valerio-Shewmaker M, Yaseen A, Kelder SH, Ross J, Gonzalez MO, Wu L, Padilla LN, Lopez KR, Lakey D, Shuford JA, Pont SJ, Boerwinkle E. Messiah SE, et al. Among authors: lakey d. Pediatr Infect Dis J. 2022 Oct 1;41(10):e409-e417. doi: 10.1097/INF.0000000000003653. Epub 2022 Aug 1. Pediatr Infect Dis J. 2022. PMID: 35939608
Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey.
Valerio-Shewmaker MA, DeSantis S, Swartz M, Yaseen A, Gonzalez MO, Kohl HWI, Kelder SH, Messiah SE, Aguillard KA, Breaux C, Wu L, Shuford J, Pont S, Lakey D, Boerwinkle E. Valerio-Shewmaker MA, et al. Among authors: lakey d. Front Public Health. 2021 Dec 14;9:753487. doi: 10.3389/fpubh.2021.753487. eCollection 2021. Front Public Health. 2021. PMID: 34970525 Free PMC article. Clinical Trial.
Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents.
Messiah SE, DeSantis SM, Leon-Novelo LG, Talebi Y, Brito FA, Kohl HW, Valerio-Shewmaker MA, Ross JA, Swartz MD, Yaseen A, Kelder SH, Zhang S, Omega-Njemnobi OS, Gonzalez MO, Wu L, Boerwinkle E, Lakey DL, Shuford JA, Pont SJ. Messiah SE, et al. Among authors: lakey dl. Pediatrics. 2022 Jun 1;149(6):e2021055505. doi: 10.1542/peds.2021-055505. Pediatrics. 2022. PMID: 35301530 No abstract available.
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey.
Swartz MD, DeSantis SM, Yaseen A, Brito FA, Valerio-Shewmaker MA, Messiah SE, Leon-Novelo LG, Kohl HW, Pinzon-Gomez CL, Hao T, Zhang S, Talebi Y, Yoo J, Ross JR, Gonzalez MO, Wu L, Kelder SH, Silberman M, Tuzo S, Pont SJ, Shuford JA, Lakey D, Boerwinkle E. Swartz MD, et al. Among authors: lakey d. J Infect Dis. 2023 Jan 11;227(2):193-201. doi: 10.1093/infdis/jiac167. J Infect Dis. 2023. PMID: 35514141 Free PMC article.
Methodology to estimate natural- and vaccine-induced antibodies to SARS-CoV-2 in a large geographic region.
DeSantis SM, León-Novelo LG, Swartz MD, Yaseen AS, Valerio-Shewmaker MA, Talebi Y, Brito FA, Ross JA, Kohl HW 3rd, Messiah SE, Kelder SH, Wu L, Zhang S, Aguillard KA, Gonzalez MO, Omega-Njemnob OS, Lakey D, Shuford JA, Pont S, Boerwinkle E. DeSantis SM, et al. Among authors: lakey d. PLoS One. 2022 Sep 9;17(9):e0273694. doi: 10.1371/journal.pone.0273694. eCollection 2022. PLoS One. 2022. PMID: 36084125 Free PMC article.
Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants.
DeSantis SM, Yaseen A, Hao T, León-Novelo L, Talebi Y, Valerio-Shewmaker MA, Pinzon Gomez CL, Messiah SE, Kohl HW, Kelder SH, Ross JA, Padilla LN, Silberman M, Tuzo S, Lakey D, Shuford JA, Pont SJ, Boerwinkle E, Swartz MD. DeSantis SM, et al. Among authors: lakey d. J Infect Dis. 2023 May 12;227(10):1164-1172. doi: 10.1093/infdis/jiad020. J Infect Dis. 2023. PMID: 36729177
SARS-CoV-2 Serostatus and COVID-19 Illness Characteristics by Variant Time Period in Non-Hospitalized Children and Adolescents.
Messiah SE, Swartz MD, Abbas RA, Talebi Y, Kohl HW 3rd, Valerio-Shewmaker M, DeSantis SM, Yaseen A, Kelder SH, Ross JA, Padilla LN, Gonzalez MO, Wu L, Lakey D, Shuford JA, Pont SJ, Boerwinkle E. Messiah SE, et al. Among authors: lakey d. Children (Basel). 2023 Apr 30;10(5):818. doi: 10.3390/children10050818. Children (Basel). 2023. PMID: 37238366 Free PMC article.
Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents.
Messiah SE, Talebi Y, Swartz MD, Sabharwal R, Han H, Bergqvist E, Kohl HW 3rd, Valerio-Shewmaker M, DeSantis SM, Yaseen A, Kelder SH, Ross J, Padilla LN, Gonzalez MO, Wu L, Lakey D, Shuford JA, Pont SJ, Boerwinkle E. Messiah SE, et al. Among authors: lakey d. Pediatr Res. 2024 Jul;96(2):525-534. doi: 10.1038/s41390-023-02857-y. Epub 2023 Oct 24. Pediatr Res. 2024. PMID: 37875728 Free PMC article.
RE: Incidence of SARS-CoV-2 Breakthrough Infections After Vaccination in Adults: A Population-Based Survey Through 1 March 2023.
DeSantis SM, Yaseen A, Hao T, León-Novelo L, Talebi Y, Valerio-Shewmaker MA, Pinzon Gomez CL, Messiah SE, Kohl HW 3rd, Kelder SH, Ross JA, Padilla LN, Silberman M, Wylie S, Lakey D, Shuford JA, Pont SJ, Boerwinkle E, Swartz MD. DeSantis SM, et al. Among authors: lakey d. Open Forum Infect Dis. 2023 Nov 29;10(12):ofad564. doi: 10.1093/ofid/ofad564. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38099238 Free PMC article. No abstract available.
Baseline characteristics of SARS-CoV-2 vaccine non-responders in a large population-based sample.
Yaseen A, DeSantis SM, Sabharwal R, Talebi Y, Swartz MD, Zhang S, Leon Novelo L, Pinzon-Gomez CL, Messiah SE, Valerio-Shewmaker M, Kohl HW 3rd, Ross J, Lakey D, Shuford JA, Pont SJ, Boerwinkle E. Yaseen A, et al. Among authors: lakey d. PLoS One. 2024 May 13;19(5):e0303420. doi: 10.1371/journal.pone.0303420. eCollection 2024. PLoS One. 2024. PMID: 38739625 Free PMC article.
50 results